Document Detail


Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.
MedLine Citation:
PMID:  9678797     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy and safety of mycophenolate mofetil (MMF) in combination with CsA and prednisolone for the treatment of acute and chronic GVHD (aGVHD and cGVHD, respectively) after BMT and PBSCT from HLA-mismatched and -matched donors was evaluated in an open single center trial. Twenty-four patients, 17-48 years of age, with acute (n = 17) and chronic GVHD (n = 7) were treated with 2 g MMF daily in addition to CsA and prednisolone. Overall grade improvement of aGVHD was found in 11 of 17 (65%) patients treated with MMF. MMF therapy in the treatment of cGVHD led to moderate improvement in three of six patients with limited cGVHD. The most common adverse hematologic events of MMF were leukopenia (n = 6), anemia (n = 4) and thrombocytopenia (n = 3). Hematological adverse events were not severe and did not require the discontinuation of MMF. In this preliminary study, we have shown that MMF can be used safely for the treatment of aGVHD. In addition, the MMF therapy resulted in significant dose reduction of prednisolone for the treatment of GVHD.
Authors:
N Basara; W I Blau; E Römer; M Rudolphi; M Bischoff; D Kirsten; H Sanchez; S Günzelmann; A A Fauser
Related Documents :
19855247 - Prospective observational study of sirolimus as primary immunosuppression after renal t...
16612277 - Early cyclosporine c0 and c2 monitoring in de novo kidney transplant patients: a prospe...
19017277 - Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipient...
12105257 - Impact of the variability of cyclosporin a trough levels on long-term renal allograft f...
715977 - Reduction in renal size associated with complete ureteric duplication.
20389147 - Donor-derived solid malignancies after hematopoietic stem cell transplantation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  22     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  1998 Jul 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  61-5     Citation Subset:  IM    
Affiliation:
Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Anemia / chemically induced
Bone Marrow Transplantation*
Chronic Disease
Cyclosporine / adverse effects,  therapeutic use
Female
Graft vs Host Disease / drug therapy*,  prevention & control
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use*
Leukopenia / chemically induced
Male
Middle Aged
Mycophenolic Acid / adverse effects,  analogs & derivatives*,  therapeutic use
Prednisolone / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 24280-93-1/Mycophenolic Acid; 50-24-8/Prednisolone; 59865-13-3/Cyclosporine; 9242ECW6R0/mycophenolate mofetil
Comments/Corrections
Comment In:
Bone Marrow Transplant. 2000 Dec;26(12):1362-3   [PMID:  11223981 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maximal preservation of renal function in patients with bilateral Wilms' tumor: therapeutic strategy...
Next Document:  Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients.